text_1: Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events
text_2: Biologics, psychiatric therapeutics, and accelerated and near–regulatory deadline approval were statistically significantly associated with higher rates of events, highlighting the need for continuous monitoring of the safety of novel therapeutics throughout their life cycle.